Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
Alternative names
3bnc117 (1 trial)
ad26.mos.hiv (1 trial)
ad35-grin (4 trials)
Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine (Kinrix) (1 trial)
dna.hiva (1 trial)
dna-hiv-pt123 (2 trials)
emtricitabine (emtriva) (3 trials)
gp140 vaccine (1 trial)
hiv glycoprotein cn54gp140 vaccine (1 trial)
measles, mumps, and rubella vaccine (MMR) (1 trial)
mva.hiva (1 trial)
mva-mosaic (1 trial)
pgdm1400 (2 trials)
pgt121 (3 trials)
psg2.hivconsv dna vaccine (1 trial)
rvsv∆g-lasv-gpc (2 trials)
tenofovir (viread) (4 trials)
tenofovir alafenamide (genvoya) (1 trial)
tgaac09 (2 trials)
vrc07-523ls (2 trials)
vrchivadv014-00-vp (1 trial)
vrc-hivdna-016-00-vp (2 trials)
vrc-hivmab080-00-ab (1 trial)
10e8.4/imab (1 trial)
3m-052-af (1 trial)
ad26.enva.01 vaccine (1 trial)
ad35-env (1 trial)
ad35-grin/env (1 trial)
ad35 investigational hiv vaccine (1 trial)
advax (2 trials)
aidsvax b/e (2 trials)
aluminum hydroxide (Gaviscon) (1 trial)
as01 (1 trial)
bg505 sosip.664 gp140 (4 trials)
bg505 sosip gt1.1 gp140 vaccine (1 trial)
chadox1.thivconsv1 (1 trial)
cmv vaccine (1 trial)
core-g28v2 60mer mrna vaccine (1 trial)
cpg 1018 (1 trial)
eod-gt8 60mer (3 trials)
genevax il-12-4532 (1 trial)
gla-lsq (1 trial)
hiv-mag (1 trial)
modified vaccinia ankara hiv vaccine (1 trial)
mva.thivconsv3 (1 trial)
mva.thivconsv4 (1 trial)
raav1-pg9dp (1 trial)
rcad26.mos1.hiv-env (1 trial)
sev-g(np) (1 trial)
sucrose (1 trial)
tbc-m4 (1 trial)
Acquired Immunodeficiency Syndrome (Phase 2)
Communicable Diseases (Phase 2)
HIV Infections (Phase 2)
Infections (Phase 2)
Vaccinia (Phase 1)
Virus Diseases (Phase 2)
Trials (41 total)
Trial APIs (51 total)